These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
445 related articles for article (PubMed ID: 33490218)
41. The emerging role of PARP inhibitors in prostate cancer. Stellato M; Guadalupi V; Sepe P; Mennitto A; Claps M; Zattarin E; Verzoni E; Valdagni R; De Braud FG; Santini D; Tonini G; Procopio G Expert Rev Anticancer Ther; 2020 Aug; 20(8):715-726. PubMed ID: 32758032 [TBL] [Abstract][Full Text] [Related]
42. Talazoparib to treat BRCA-positive breast cancer. Guney Eskiler G Drugs Today (Barc); 2019 Jul; 55(7):459-467. PubMed ID: 31347614 [TBL] [Abstract][Full Text] [Related]
43. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment? Liu JF; Matulonis UA Curr Oncol Rep; 2016 May; 18(5):29. PubMed ID: 26984416 [TBL] [Abstract][Full Text] [Related]
44. Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer. Musella A; Bardhi E; Marchetti C; Vertechy L; Santangelo G; Sassu C; Tomao F; Rech F; D'Amelio R; Monti M; Palaia I; Muzii L; Benedetti Panici P Cancer Treat Rev; 2018 May; 66():7-14. PubMed ID: 29605737 [TBL] [Abstract][Full Text] [Related]
45. PARP Inhibition and Beyond in BRCA-Associated Breast Cancer in Women: A State-Of-The-Art Summary of Preclinical Research on Risk Reduction and Clinical Benefits. Pauwels EKJ; Bourguignon MH Med Princ Pract; 2022; 31(4):303-312. PubMed ID: 35636395 [TBL] [Abstract][Full Text] [Related]
46. Veliparib: a new therapeutic option in ovarian cancer? Ghisoni E; Giannone G; Tuninetti V; Genta S; Scotto G; Aglietta M; Sangiolo D; Mittica G; Valabrega G Future Oncol; 2019 Jun; 15(17):1975-1987. PubMed ID: 31074636 [TBL] [Abstract][Full Text] [Related]
47. Integration of PARP-inhibitors in ovarian cancer therapy. Pietragalla A; Ciccarone F; Nero C; Scambia G; Lorusso D; Daniele G Explor Target Antitumor Ther; 2020; 1(3):171-182. PubMed ID: 36046198 [TBL] [Abstract][Full Text] [Related]
48. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations. Miller RE; Ledermann JA Clin Adv Hematol Oncol; 2016 Sep; 14(9):704-11. PubMed ID: 27673289 [TBL] [Abstract][Full Text] [Related]
49. [Cancer therapy by PARP inhibitors]. Seimiya H Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686 [TBL] [Abstract][Full Text] [Related]
50. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis. Chung C; Lee R J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817 [TBL] [Abstract][Full Text] [Related]
51. PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost. Hennes ER; Dow-Hillgartner EN; Bergsbaken JJ; Piccolo JK J Oncol Pharm Pract; 2020 Apr; 26(3):718-729. PubMed ID: 31902284 [TBL] [Abstract][Full Text] [Related]
52. PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date. Nizialek E; Antonarakis ES Cancer Manag Res; 2020; 12():8105-8114. PubMed ID: 32982407 [TBL] [Abstract][Full Text] [Related]
53. PARP inhibitors in ovarian cancer. Franzese E; Centonze S; Diana A; Carlino F; Guerrera LP; Di Napoli M; De Vita F; Pignata S; Ciardiello F; Orditura M Cancer Treat Rev; 2019 Feb; 73():1-9. PubMed ID: 30543930 [TBL] [Abstract][Full Text] [Related]
55. PARP and PARG inhibitors in cancer treatment. Slade D Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455 [TBL] [Abstract][Full Text] [Related]
56. Pamiparib for germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube or primary peritoneal cancer. Skrzypczyk-Ostaszewicz A Drugs Today (Barc); 2022 Jun; 58(6):299-309. PubMed ID: 35670707 [TBL] [Abstract][Full Text] [Related]
57. Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer. Lin ZP; Zhu YL; Lo YC; Moscarelli J; Xiong A; Korayem Y; Huang PH; Giri S; LoRusso P; Ratner ES PLoS One; 2018; 13(11):e0207399. PubMed ID: 30444904 [TBL] [Abstract][Full Text] [Related]
58. Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer. Ledermann JA; Pujade-Lauraine E Ther Adv Med Oncol; 2019; 11():1758835919849753. PubMed ID: 31205507 [TBL] [Abstract][Full Text] [Related]
59. [Abnormalities of DNA repair and gynecological cancers]. Auguste A; Leary A Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544 [TBL] [Abstract][Full Text] [Related]
60. Poly(ADP-ribose) polymerase activity and inhibition in cancer. Dulaney C; Marcrom S; Stanley J; Yang ES Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]